2016-05-31 13:03:13 UTC

May 31, 2016

The two-day conference, organized by the AGA Center for Diagnostics and Therapeutics, will take place Oct. 27-28.

The process of developing new GI diagnostics and therapeutics is fraught with challenges, wrong turns and dead ends. Learn to anticipate these potential barriers and navigate the drug development maze by attending the first annual AGA Drug Development Conference: Clinical Endpoints in Upper GI Disorders

The two-day conference, organized by the AGA Center for Diagnostics and Therapeutics (CDT), opens Oct. 27 in Washington, DC. It will focus on the critical need to facilitate development of new medicines and biomarkers for upper GI disorders.

Join your colleagues and all stakeholders (researchers, clinicians, policymakers, industry and patient advocacy groups) as we:

  • Identify promising new medicines and diagnostic tests for upper GI disorders.
  • Learn how to define appropriate clinical endpoints and improve clinical trial designs.
  • Network and collaborate with colleagues and other stakeholders in drug development.
  • Make our voices heard in an open forum and in Q&A sessions.

Learn more and register today to take advantage of early registration discounts through Sept. 16.

More on Dyspepsia / Non-Ulcer Dyspepsia